SKYCovione GSK
Letzte Änderung:
SK bioscience
SK bioscience and GSK: adjuvanted COVID-19 vaccine SKYCovione.
Other Vaccines GSK:
Medicago’s plant-derived vaccine candidate against COVID-19 uses Coronavirus-Like-Particle (CoVLP) technology with the vaccine composed of recombinant spike (S) glycoprotein expressed as virus-like-particles (VLPs) co-administered with GSK’s pandemic adjuvant.
GSK forscht daneben zusammen mit Curevac an einem weiteren Impfstoffkandidaten; mehr dazu unter "Impfungen" ->"Curevac".
Quellen (5)
-
SK bioscience and GSK’s Adjuvanted COVID-19 Vaccine Candidate Meets Coprimary Objectives in a Phase III Study; Biologics License Application Submitted for SKYCovione™(GBP510/GSK adjuvant) in South Korea
skbioscience.co.kr, hinzugefügt am 30.04.2022
-
Medicago and GSK announce the approval by Health Canada of COVIFENZ®, an Adjuvanted Plant-Based COVID-19 Vaccine
medicago.com, hinzugefügt am 06.03.2022
-
Medicago and GSK announce positive Phase 3 efficacy and safety results for adjuvanted plant-based COVID-19 vaccine candidate
gsk.com, hinzugefügt am 09.12.2021
-
SK bioscience and GSK start Phase 3 trial of adjuvanted COVID-19 vaccine candidate
gsk.com, hinzugefügt am 02.10.2021
-
Medicago and GSK start Phase 3 trial of adjuvanted COVID-19 vaccine candidate
gsk.com, hinzugefügt am 17.03.2021